ClinicalTrials.gg
CompletedNCT06128967REVIVEUpdated Apr 13, 2026

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

A Phase 3 interventional study of Fluvoxamine Maleate 100 MG and Placebo in Long COVID-19 Syndrome and Chronic Fatigue Syndrome, sponsored by Cardresearch. Completed at 6 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Cardresearch · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
399
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.

Enrollment
Largest of 18
399 · median 57
Started
2023
with 5 others
Phase 3
3 of 21
2 open now
Registered
12th of 21
by date
Lead sponsor
1 of 21
Cardresearch

Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 3, and was the 12th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval

Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals after an acute episode of COVID-19, even in those who had a mild and oligosymptomatic SARS-CoV-2 infection. Around 40% of these patients present symptoms that significantly compromise their daily activities.

There is increasing evidence that LONG COVID is accompanied by dysregulated, persistent and uncontrolled inflammation, often accompanied by the development of an autoreactive immune response, including autoantibodies. Symptoms can last months or years, particularly in cases of chronic fatigue syndrome, with significant proportions of individuals having significant chronic impairment, preventing the performance of work and social activities.

Read the detailed description

There is currently no approved therapies for Long COVID. Several clinical trials have been developed to address this clinical condition, however the results were based on small-scale pilot studies. We developed this adaptive, large-scale, prospective, double-blind clinical trial to evaluate the effect of chronic immune-inflammatory modulation on persistent Long-COVID symptoms.

03

Conditions studied

  • Long COVID-19 Syndrome
  • Chronic Fatigue Syndrome

Keywords

  • Long COVID-19 Syndrome
  • Fluvoxamine
  • Metformin
  • Adaptive Trial Design
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older at the time of screening.
  2. Willing and able to provide written , or with a legal representative who can provide informed consent (where approved locally and nationally).
  3. Previous confirmed case of SARS-CoV-2 infection (e.g., reports having a positive nucleic acid amplification test or a professional-use SARS-CoV-2 rapid antigen diagnostic test or positive self-test).
  4. Participants with a clinical picture compatible with LONG COVID according to international definitions: (www.nice.org.uk/guidance/ng188, https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID -19_condition-Clinical_case_definition-2021.1), and fatigue symptoms with an average score of at least 03 on the Fatigue Analog Scale (FSS)
  5. Last COVID-19 episode within 24 months of screening.
  6. Not currently hospitalized or requiring hospitalization, or having been hospitalized in an intensive care center at the time of the COVID-19 episode.

6. Participants with the following vital data:

  1. Heart Rate between 55 and 100 bpm;
  2. Temperature below 38o C;
  3. Oxygen saturation ≥ 95%. 7. Patients of or with partners of childbearing potential must agree to use adequate during the study and up to 90 days of follow-up.

    8. The symptoms of fatigue cannot be attributed to any other cause (in the researcher's opinion).

    9. Willingness to follow all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known acute SARS-CoV-2 infection;
  2. Inability to understand the content of the Form or to follow the study procedures;
  3. Known previous diagnosis of malignant encephalomyelitis/chronic fatigue syndrome, unrelated to SARS-CoV-2 infection;
  4. Known pre-existing dysautonomia, unrelated to SARS-CoV-2 infection;
  5. Diabetes mellitus (exclusion criteria for the Metformin and Metformin Placebo arm);
  6. Known Creatinin Clearance \< 30 ml/ min or under chronic renal replacement therapy;
  7. Known stroke within 3 months prior to screening;
  8. Known severe anemia, defined as \< 8 g/dl;
  9. (BMI) > 40.
  10. Known diagnosis of Lyme disease;
  11. Any use of illicit drugs not related to marijuana within 30 days prior to informed consent;
  12. Pregnant women or women of childbearing age who do not agree to practice an effective method of within 90 days from the date of signing this consent form;
  13. Breastfeeding women;
  14. Expected hospitalization for elective surgical procedures that will ensure hospitalization > 48 hs;
  15. for Metformin arm eligibility:

    1. Participant currently on metformin use;
    2. Participants with known \< 30 ml/min, history of KDIGO IV or under renal replacement therapy;
  16. Contra-indications for Fluvoxamin arm eligibility:

    a. Current use of serotonin reuptake inhibitors (donepezil, Fluoxetine, Escitalopran, Paroxetine

  17. Severe current comorbid psychiatric disorder (e.g., clinical depression, anxiety, sleep disorder, eating disorder, substance abuse), uncontrolled and associated with significant symptoms or requiring the use of a medication contraindicated in this research ;
  18. Clinical history of moderate to severe hepatic impairment or liver cirrhosis with classification C or greater;
  19. Clinical history of severe lung disease with significant limitation of activities;
  20. Inability of the participant to give consent or adhere to the procedures proposed in the study;
  21. Taking medications which are known to cause a known side effect of chronic fatigue (except for participants with cardiovascular disease and chronic use of beta-blockers);
  22. Known and/or intolerance to Fluvoxamine or Metformin;
  23. Any clinical condition which, in the investigator's opinion, may prevent participation in this research.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
399 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo talc pills of same shape, color, weight dispensed in coded bottles. Each bottle contains 120 pills

    Drug: Fluvoxamine Maleate 100 MG · Drug: Metformin Extended Release Oral Tablet

  • Active comparator
    Fluvoxamine 100 mg

    Fluvoxamine maleate 100 mg pills dispensed in coded bottles. Each bottle contains 120 pills

    Drug: Placebo

  • Active comparator
    Metformin XR 500 mg

    Metformin 500 mg Extended release pills dispensed in coded bottles. Each bottle contains 120 pills

    Drug: Placebo

Interventions

  • DrugFluvoxamine Maleate 100 MG

    Fluvoxamine Maleate 100 mg each pills

  • DrugPlacebo

    Placebo talc pills of same shape, color, weight if compared with active comparator

  • DrugMetformin Extended Release Oral Tablet

    Metformin Extended release oral tablets of 750 mg each pill

06

What researchers measure

Primary outcomes

  1. Improvement on Fatigue Severity Score Scale (FSS)

    Improvement on Fatigue Severity Score Scale (FSS)

    Time frame: Day 60 after randomization

Secondary outcomes

  1. Improvement on Fatigue Severity Score Scale (FSS)

    Improvement on Fatigue Severity Score Scale (FSS)

    Time frame: Day 30 after randomization

  2. Improvement on Fatigue Severity Score Scale (FSS)

    Improvement on Fatigue Severity Score Scale (FSS)

    Time frame: Day 30 post Study Drug Termination (Day 90 after randomization)

  3. Reduction on any cause hospitalization

    Reduction on any cause hospitalization

    Time frame: Day 60 after randomization

  4. Safety of metformin

    Safety of metformin (intention to treat analysis)

    Time frame: Since randomization up to Day 60 (last IMP dose)

  5. Safety of Fluvoxamine

    Safety of Fluvoxamine (intention to treat analysis)

    Time frame: Since randomization up to Day 60 (last IMP dose)

  6. Death of any cause

    Occurrence of Death of any cause

    Time frame: Since randomization up to Day 60 (last IMP dose)

07

Study locations

6 sites
  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
    Belo Horizonte, Minas Gerais 30150240, Brazil
  • City of Brumadinho
    Brumadinho, Minas Gerais 35.460-000, Brazil
  • Governador Valadares City Public Health Authority
    Governador Valadares, Minas Gerais, Brazil
  • City of Ibirité Public Health Authority
    Ibirité, Minas Gerais, Brazil
  • Sociedade Padrao de Educacao Superior
    Montes Claros, Minas Gerais, Brazil
  • Universidade Federal de Ouro Preto
    Ouro Preto, Minas Gerais 35400000, Brazil
08

References and documents

Publications

  • Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Ferreira TS, Reis LLF, Figueiredo Guimaraes Almeida AP, Menezes Amaral M, Savassi LCM, de Souza Campos VH, Campos Simplicio MI, Barra Ribeiro L, de Souza Medeiros T, Campos Siqueira T, Vieira TS, Drumond Rausse N, Garofolo TC, Fagundes Silva EC, Harari O, D'Urso G, Forrest JI, Park J, Nachega JB, Lindsell C, Glenn JS, Thorlund K, Dybul M, Mills EJ; REVIVE Investigators. The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial. Ann Intern Med. 2026 May;179(5):621-628. doi: 10.7326/ANNALS-25-03959. Epub 2026 Mar 31. PubMed 41911553 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are prone to share patient level information data to specific researchers that share the same intention. Data sharing request shall be submitted to a local committee for approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: A year after protocol termination

Access criteria: To be defined

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jul 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 13, 2023
StartActual
Oct 18, 2023
Primary completionActual
Jul 1, 2025
CompletionActual
Aug 1, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128967
Lead sponsor
Cardresearch
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 18, 2023
Primary completion
Jul 1, 2025
Completion
Aug 1, 2025
Last update
Apr 13, 2026

Study contacts

Gilmar Reis, MD,PhD.
study chair · Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion